Novasep Launches Dedicated Fill/Finish Operations in Belgium

October 10, 2019
Pharmaceutical Technology Editors

Novasep has revealed in an Oct. 1, 2019 press release that is has launched a dedicated unit in Seneffe, Belgium, offering fill/finish clinical and commercial services for biological products.

Novasep has revealed in an Oct. 1, 2019 press release that is has launched a dedicated unit in Seneffe, Belgium, offering fill/finish clinical and commercial services for biological products. The dedicated unit, Senefill, forms part of Novasep’s flagship for the manufacturing of commercial viral vectors, Senrise-IV, and will provide standalone fill/finish services in addition to integrated drug product manufacturing, ranging from formulation to packaging. Operations undertaken at Senefill will support Novasep’s key biopharmaceutical markets.

“Senefill is a major step for Novasep to achieve its growth strategy, Rise-2,” said Michel Spagnol, chairman and CEO of Novasep, in the press release. “This unit strongly distinguishes Novasep from its competitors in the market for viral vector drug product manufacturing services. It was crucial for us to be able to meet the growing needs of our clients for targeted and innovative therapies and address patients’ needs.”

Source: Novasep